Organon & Co. (NYSE:OGN) Shares Bought by Advisors Asset Management Inc.

Advisors Asset Management Inc. boosted its stake in Organon & Co. (NYSE:OGN) by 6.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 706,429 shares of the company’s stock after buying an additional 45,865 shares during the quarter. Advisors Asset Management Inc.’s holdings in Organon & Co. were worth $10,540,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of OGN. Prospera Private Wealth LLC acquired a new stake in Organon & Co. in the 3rd quarter valued at $25,000. Horizon Bancorp Inc. IN increased its stake in shares of Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after acquiring an additional 1,585 shares during the period. Larson Financial Group LLC boosted its holdings in Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after buying an additional 1,734 shares in the last quarter. Riverview Trust Co boosted its stake in Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock worth $36,000 after purchasing an additional 1,292 shares during the period. Finally, Versant Capital Management Inc boosted its stake in shares of Organon & Co. by 92.2% during the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after buying an additional 1,324 shares during the period. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on OGN. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Barclays decreased their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, Morgan Stanley decreased their price target on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $20.80.

Organon & Co. Stock Up 2.1 %

Shares of OGN stock opened at $15.63 on Tuesday. The firm has a fifty day moving average of $15.46 and a 200-day moving average of $16.60. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The company has a market capitalization of $4.03 billion, a price-to-earnings ratio of 4.69, a P/E/G ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. As a group, equities research analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 7.17%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.’s dividend payout ratio (DPR) is currently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.